儿科急诊室的安全事故:发生率,特征和中心之间的变化. 一个全国性的多中心研究
Dolores Beteta Fernández1, Carlos Pérez Cánovas1, Rosa Belén Martínez Egea1
1Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Anales de pediatria
|October 24, 2025
概括
患者安全事件在儿科急诊室很常见,有8.5%的儿童经历过. 许多事故是可以预防的,并且与组织或通信问题有关,这凸显了改善安全策略的必要性.
科学领域:
- 医疗保健管理的管理
- 患者安全 患者安全
- 儿科急救医学 儿科急救医学
背景情况:
- 儿科急诊室 (PED) 面临着由于工作量和患者的脆弱性而带来的高患者安全风险.
- 关于PED中安全事故的流行率和相关因素的证据有限.
- 了解这些事件对于制定有效的改进策略至关重要.
研究的目的:
- 确定PED中患者安全事件的发生率.
- 描述这些事件的特征.
- 识别与它们发生相关的因素.
主要方法:
- 进行了一项多中心的观察性描述性研究.
- 使用了回顾性图表审查和结构化事件报告.
- 在西班牙九家医院收集了1056名儿科患者的数据.
主要成果:
- 8.5%的儿科患者至少经历过一次安全事故.
- 大多数事件造成无或轻度/中度伤害;13%是可以预防的.
- 事件与组织,沟通或人为因素有关,医院之间的差异很大.
结论:
- 在PED中,患者安全事件是经常发生的,并且部分是可以预防的.
- 中心之间的变化表明机构结构和文化因素是有影响力的.
- 需要适应环境的策略来增强安全文化和风险管理.
相关概念视频
Types of Reports II: Incident or Occurrence Report
1.2K
An Incident or Occurrence Report in a healthcare setting is a crucial document used to record any unexpected occurrence that may or may not have affected a patient, employee, or visitor. Such reports are critical to improving patient safety and include all details leading up to and including the event.
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
1.2K
Pharmacokinetics in Pediatric Patients: Drug Distribution
251
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251
Pharmacokinetics in Pediatric Patients: Drug Excretion
209
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
241
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
241
Drug Dosing: Infants and Children
250
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
250
Pharmacokinetics in Pediatric Patients: Drug Metabolism
191
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
191


